Taisho Pharmaceutical Swings To Quarterly Loss
This article was originally published in PharmAsia News
Executive Summary
Taisho revised its estimated business results for the first half of fiscal year 2008. Instead of ¥9.5 billion in profit, the company now estimates ¥1 billion in loss. The revision is a reflection of a ¥13.3 billion loss due to share price reduction in Taisho's subsidiary Biofermin. Taisho also reduced its net profit for the full fiscal year to ¥10.5 billion from previous estimates of ¥22.5 billion. (Click here for more - Japanese language